SUZHOU, China, Feb. 10, 2025 /PRNewswire/ — CStone Pharmaceuticals (“CStone”, HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that its key product, Cejemly^® (sugemalimab), has been included in the European Society for Medical Oncology (ESMO) Non-Oncogene-Addicted Metastatic Non-Small-Cell Lung Cancer (NSCLC) Living Guideline. Sugemalimab is recommended as a first-line combination therapy for both squamous and non-squamous NSCLC, with substantial clinical benefits. This is a significant milestone in sugemalimab’s global journey and provides critical support for our efforts to expand market access, enter the markets, and reach patients.

According to the ESMO Guideline:

• For patients with squamous NSCLC, performance status (PS) 0-1, regardless of tumour PD-L1 status and without contraindications for immune checkpoint inhibitors (ICI), sugemalimab-platinum-doublet chemotherapy is recommended as a Level [I, A] first-line combination therapy, with an ESMO-MCBS v1.1 score of 4, indicating substantial clinical benefit. Link to guideline: PS 0-1 & any expression of PD-L1 | ESMO
• For patients with non-squamous NSCLC, PS 0-1, regardless of tumour PD-L1 status and without contraindications for ICI, sugemalimab-platinum-based chemotherapy is recommended as a Level [I, A] first-line combination therapy, with an ESMO-MCBS v1.1 score of 4, also indicating substantial clinical benefit. Link to guideline: PS 0-1 & any expression of PD-L1 | ESMO

These recommendations are supported by robust clinical data from the Phase III GEMSTONE-302 trial, which demonstrated significant benefits in progression-free survival (PFS) and overall survival (OS) with sugemalimab plus platinum-based chemotherapy, compared to placebo plus platinum-based chemotherapy. Notably, sustained and consistent benefits were observed across various histological subtypes and PD-L1 expression levels. Long-term survival data from the GEMSTONE-302 study were presented at the 2024 ESMO Annual Meeting.

Currently, sugemalimab has been approved in China, the EU, and the UK for first-line treatment of advanced NSCLC. After successfully establishing commercial partnerships in dozens of countries in Switzerland, Central and Eastern Europe, the Middle East, Africa, and Latin America, CStone is actively pursuing strategic commercial partnerships in Western Europe, Southeast Asia, and Canada. This effort is in parallel with the overseas registration and launch process for other indications of sugemalimab.

About Cejemly^® (sugemalimab)

The anti-PD-L1 monoclonal antibody Cejemly^® (sugemalimab) was developed by CStone using OmniRat^® transgenic animal platform, which allows creation of fully human antibodies in one step. Sugemalimab is a fully human, full-length anti-PD-L1 immunoglobulin G4 (IgG4) monoclonal antibody, which may reduce the risk of immunogenicity and toxicity for patients, a unique advantage over similar drugs.

The National Medical Products Administration (NMPA) of China has approved sugemalimab for five indications:

• In combination with chemotherapy as first-line treatment of patients with metastatic squamous and non-squamous NSCLC;
• For the treatment of patients with unresectable Stage III NSCLC whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy;
• For the treatment of patients with relapsed or refractory extranodal NK/T-cell lymphoma;
• In combination with fluorouracil and platinum-based chemotherapy as first-line treatment of patients with unresectable locally advanced, recurrent or metastatic ESCC; and
• In combination with fluoropyrimidine- and platinum-containing chemotherapy as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma with a PD-L1 expression (Combined Positive Score [CPS] ≥5).

The European Commission (EC) has approved sugemalimab in combination with platinum-based chemotherapy for the first-line treatment of patients with metastatic NSCLC with no sensitizing EGFR mutations, or ALK, ROS1 or RET genomic tumor aberrations.

The Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom has approved the marketing authorization application for sugemalimab in combination with platinum-based chemotherapy for first-line treatment of metastatic NSCLC with no sensitizing EGFR mutations, or ALK, ROS1 or RET genomic tumor aberrations.

About CStone 

CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies. Dedicated to addressing patients’ unmet medical needs in China and globally, the Company has made significant strides since its inception. To date, the Company has successfully launched 4 innovative drugs and secured approvals for 16 new drug applications (NDAs) covering 9 indications. The company’s pipeline is balanced by 17 promising candidates, featuring potentially first-in-class or best-in-class antibody-drug conjugates (ADCs), multispecific antibodies, immunotherapies and precision medicines. CStone also prides itself on a management team with comprehensive experiences and capabilities that span the entire drug development spectrum, from preclinical and translational research to clinical development, drug manufacturing, business development, and commercialization. For more information about CStone, please visit www.cstonepharma.com.

Forward-looking statements 

The forward-looking statements made in this article only relate to events or information as of the date when the statements are made in this article. Except as required by law, we undertake no obligation to update or publicly revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. All statements in this article are made on the date of publication of this article and may change due to future developments.

Disclaimer: only for communication and scientific use by medical and health professionals, it is not intended for promotional purposes.

GUANGZHOU, China, Feb. 10, 2025 /PRNewswire/ — The second phase of the 55th edition of the China International Furniture Fair (Guangzhou) (CIFF Guangzhou 2025), featuring the Office and Commercial Space, as well as the CIFM/interzum guangzhou, is set to take place from March 28 to 31, 2025, at the Canton Fair Complex in Guangzhou.

The Office and Commercial Space exhibition, themed “Sustainability,” will present pioneering solutions for office spaces and the latest trends in commercial space design. Spanning 24 exhibition halls in Areas A, B, and D of the Canton Fair Complex, it will cover an impressive area of over 240,000 square meters and feature more than 1,000 exhibitors.

The exhibition will feature the Office Environment zone, where comprehensive solutions will be offered, and the latest office design trends will be unveiled. The Office Seating zone will address the challenges of prolonged sitting with various ergonomics innovations that focus on wellness in offices. The Public Commercial Space will cater to multiple scenarios, providing one-stop solutions for commercial spaces.

Design and trends will take center stage with special exhibitions curated in collaboration with professional curators, designers, and media personnel. These exhibitions will focus on cutting-edge design trends, offering a visual feast and a source of inspiration for attendees.

The CIFM/interzum guangzhou will operate under the theme “Engine of New Productivity Boosters in the Home Industry,” showcasing advanced concepts and technologies in the upstream production of home furnishings. This fair segment will focus on the entire industrial chain of home production, with continuous upgrades to the exhibition zones.

The Machinery zone will highlight trends in intelligent, automated, and integrated development, while the Furniture Hardware zone will present smart technology concepts and comprehensive hardware solutions. The Furniture Materials zone will offer one-stop efficient production solutions and explore innovative material designs.

The four-day event will also bring together leading domestic and international brands, showcasing achievements in the upstream home furnishing industry chain. A series of industry activities will be held to provide insights into industry trends and empower high-quality development.

CIFF Guangzhou 2025 promises to leave a lasting impact on the industry, setting new standards for innovation and sustainability in furniture design and production. Attendees are encouraged to explore the opportunities and insights offered at the event, which continues to shape the future of the furniture industry.

Visit https://www.ciff-gz.com/en/  for more information.

SINGAPORE, Feb. 10, 2025 /PRNewswire/ — Singapore-based asset manager Seraya Partners has launched AQX, a Tokyo-based digital infrastructure investment platform, in partnership with industry veteran Matthias Vukovich.

AQX will target investments in shared telecom infrastructure and AI-enabling digital infrastructure across the APAC region, with a special focus on the Japanese market.

Seraya Partners, headquartered in Singapore, is the first Asia-based independent private equity fund focused on next-generation infrastructure investments with $1.3 billion in AUM across its funds and co-investment vehicles.

The new investment platform AQX is led by CEO Matthias Vukovich, a seasoned expert in Japan’s digital infrastructure space. Starting 2020, Matthias has held executive roles at digital infrastructure portfolio companies under Warburg Pincus Asia, including serving as CFO of Converge ICT, a publicly listed Philippine fiber broadband operator. In this role, he successfully led Converge through its Initial Public Offering (IPO). With over 12 years at Morgan Stanley as a TMT banker in Tokyo, London, and Hong Kong, Matthias was involved in some of the largest M&A, IPO, and private fundraising deals in the digital infrastructure sector.

“We are thrilled to partner with Matthias, who brings a unique combination of extensive digital infrastructure financing and investment expertise, along with a deep understanding of the Japanese market. Together, we aim to invest in next-generation, technology-enabled digital infrastructure assets across Japan and the broader APAC region,” said James Chern, Managing Partner and CIO of Seraya Partners.

“Japan is the world’s third-largest digital infrastructure market, following the United States and China, in terms of deployed capex across telecom towers, optical fiber, and data center assets. However, the provision of shared carrier-neutral telecom infrastructure remains limited, opening investment opportunities for digital infrastructure specialists and platform builders. The recent surge in hyperscale data center projects in Japan will lead to the build-out of broader AI infrastructure asset classes, which we aim to capitalize on through AQX,” said Matthias Vukovich, CEO and founder of AQX K.K.

The AQX brand combines “AQ,” which means “permanent” in Japanese (永久), and a green “X,” symbolizing energy-efficient digital transformation. “Our brand embodies AQX’s mission to invest in highly resilient infrastructure that will drive sustainable digital transformation across society,” said Matthias.

PARIS, Feb. 10, 2025 /PRNewswire/ — 2025 IMCAS World Congress, the world’s largest scientific aesthetics congress, was grandly held in Paris from January 30 to February 1, celebrating its 26th anniversary.

Singclean Medical showcased its flagship HA fillers, Singfiller and Singderm, along with a range of regenerative medical aesthetics innovations at IMCAS. Meanwhile, Singclean successfully held the inaugural Singclean Global Aesthetic Master Symposium with Young Plastic Surgeon Medical Beauty Service Co.,Ltd. and Lazeo, the leading aesthetic medicine center in France. The event brought together global experts to explore the latest advancements in injection techniques and promote the exchange of Eastern and Western aesthetic concepts and further infuse new life into the global aesthetic medicine industry.

The grand opening of the Singclean Global Aesthetic Master Symposium was honored to welcome renowned international plastic surgeon Dr. Matt Stefanelli and German plastic surgeon Dr. Sercan. Dr. Sercan shared his insights on the evolving trends in Western aesthetic medicine, highlighting the increasing demand for multi-site, multi-dose procedures and the increasing number of male patients seeking aesthetic treatments.

The Symposium was also featured by a presentation by Dr. You Xi, the Champion of Singfiller International Injection Competition, to share her expertise in using Singfiller to achieve exceptional results in both inner and outer facial contouring.

Fostering local academic leadership was a key focus of the Symposium. To gain deeper insights, Ms. Luo Laidi, Global Business Director of Singclean, led a team to visit Lazeo, a leader in the field of aesthetic medicine in Europe, with 170 medical aesthetic clinics in France and Belgium. The visit offered a firsthand look at Lazeo’s advanced treatment procedures and meticulous services.

Through a live demonstration, Dr. You Xi showcased the transformative power of Singderm in creating a more defined and youthful facial contour.

Singclean’s regenerative medical aesthetic products, including Calcium Hydroxylapatite, Poly-L-lactic Acid, and Polydeoxyribonucleotide also attracted much attention in the Symposium.

In 2025, Singclean Medical will continue the global tour of its Injection Masterclass, keep inviting renowned international aesthetic experts to conduct a series of workshops and training sessions. These events aim to facilitate knowledge exchange and collaboration among medical professionals worldwide, driving the advancement of the global aesthetic medicine industry.

BARCELONA, Spain, Feb. 10, 2025 /PRNewswire/ — At ISE 2025 in Barcelona, Unilumin Group once again demonstrated its industry leadership by winning the prestigious Inavation Awards for its Upanel II MIP. As one of the AV industry’s most influential accolades, this award recognizes Unilumin’s relentless pursuit of innovation and excellence in LED display technology. The achievement underscores the company’s strong R&D capabilities and its commitment to delivering cutting-edge solutions to the global market.

Beyond this remarkable win, Unilumin made a powerful statement at ISE 2025 with a showcase of its latest innovations. The company unveiled three new products—Unatural, Udesign SV, and Uslim III O—alongside its Metasight platform and cinema solutions. These innovations attracted significant attention, with visitors experiencing firsthand the future of LED display technology.

Unilumin’s multi-brand presence, featuring Unilumin, LAMPRO, and ROE Visual, ensured comprehensive market coverage, meeting diverse industry needs. To strengthen global partnerships, Unilumin hosted an exclusive Customer Appreciation Dinner, bringing together industry leaders for strategic discussions, a grand signing ceremony, and interactive activities.

With this latest international recognition and a continued commitment to innovation, Unilumin is setting new benchmarks in LED technology, driving the industry forward and empowering businesses worldwide.

For more information, please visit https://www.unilumin.com/